© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > GSK620
<< Back to March
BD2 domain selective BET inhibitor
oral efficacy in 3 inflammation models
from SBDD of a BD2-selective HTS hit
Science, Mar. 19, 2020
GlaxoSmithKline, Stevenage, UK
GSK620 (GlaxoSmithKline (GSK) oral in vivo BD2 domain selective BET inhibitor)
Unlock this content with a Premium membership to read it now.